-
1 month ago | 
alzres.biomedcentral.com | Frederikke Kragh |Mathias Holsey |Anja Hviid |Steen Gregers |Mathias Holsey Gramkow |Anja Hviid Simonsen | +8 more
Correction: Short‑term variability of Alzheimer’s disease plasma biomarkers in a mixed memory clinic cohort Correction Open access Published: 21 May 2025 Alzheimer's Research & Therapy volume 17, Article number: 110 (2025) Cite this article The Original Article was published on 21 January 2025 Correction: Alz Res Therapy 17, 26 (2025)Following publication of the original article [1], the coloured lines legend (red AD, blue nonAD) to Fig.
-
1 month ago | 
alz-journals.onlinelibrary.wiley.com | Nicholas Ashton |Andrea L. Benedet |Guglielmo Di Molfetta |Ilaria Pola
1 BACKGROUND Discovery plasma proteomics has long since demonstrated a differential signal in the blood of patients clinically diagnosed with Alzheimer's disease (AD).1, 2 These earlier studies used agnostic methods to discover novel biomarkers—proteomic technologies not predicated on any a priori hypotheses in a case-control approach1, 3-6 but later evolved to an endophenotype design based on pathology; brain atrophy measures,1, 7-9 cerebrospinal fluid (CSF) biomarkers,10 or amyloid beta...
-
2 months ago | 
alz-journals.onlinelibrary.wiley.com | Ilaria Pola |Nicholas Ashton |Wagner S. Brum |Nesrine Rahmouni
1 BACKGROUND Alzheimer's disease (AD) is a progressive pathophysiological process characterized by the accumulation of amyloid-β (Aβ) and tau proteins, ultimately leading to neurodegeneration and cognitive decline.1, 2 In this context, neuroinflammation has been suggested as a significant contributor to AD progression.3, 4 Studies in mouse models of Aβ and tau suggest that microglial reactivity may accelerate Aβ plaque deposition and tau spreading, with immune-related alterations observed in...
-
2 months ago | 
alz-journals.onlinelibrary.wiley.com | Shorena Janelidze |Nicholas Ashton |Ulrika Nordstrom |Anna Orduña Dolado
1 BACKGROUND Cerebrospinal fluid (CSF) tests for amyloid beta (Aβ) peptides (Aβ42 and Aβ40) and phosphorylated tau-181 (p-tau181) have been used for several decades as biomarkers of Alzheimer's disease (AD).1 More recently, CSF p-tau181/Aβ42 and Aβ42/Aβ40 were approved by the U.S. Food and Drug Administration (FDA) to diagnose AD.2-4 Furthermore, during the past 4 years, blood-based p-tau biomarkers of AD (and p-tau217, in particular) have been applied extensively in research settings and...
-
Feb 26, 2025 | 
alz-journals.onlinelibrary.wiley.com | Yara Yakoub |Fernando Gonzalez-Ortiz |Nicholas Ashton |Christine Déry
1 BACKGROUND The core pathological hallmarks that define Alzheimer's disease (AD) are plaque-forming aggregates of amyloid beta (Aβ) and neurofibrillary tangles of hyper-phosphorylated tau (p-tau).
-
Jan 6, 2025 | 00581-4/fulltext&sz=64)
thelancet.com | Nicholas Ashton |SUN CITY
In 2014, when eBioMedicine launched its first issue, in vivo biomarkers to detect the hallmarks of Alzheimer’s disease (AD) were entirely restricted to position emission tomography (PET) and cerebrospinal fluid (CSF). There was certainly limited enthusiasm that a comparable determination about AD pathology or neurodegeneration could be made from an easily accessible biofluid such as blood.
-
Dec 30, 2024 | 
alzres.biomedcentral.com | Maxime Van Egroo |Elise Beckers |Nicholas Ashton |Kaj Blennow |Henrik Zetterberg
ReferencesVan Egroo M, Narbutas J, Chylinski D, Villar González P, Maquet P, Salmon E, et al. Sleep–wake regulation and the hallmarks of the pathogenesis of Alzheimer’s disease. Sleep. 2019;42:1–13. Google Scholar Rigat L, Ouk K, Kramer A, Priller J. Dysfunction of circadian and sleep rhythms in the early stages of Alzheimer’s disease. Acta Physiol. 2023;238:1–13. Google Scholar Winer JR, Morehouse A, Fenton L, Harrison TM, Ayangma L, Reed M, et al.
-
Dec 23, 2024 | 
alzres.biomedcentral.com | Georgette Argiris |Muge Akinci |Cleofé Peña-Gómez |Eleni Palpatzis |Marina García-Prat |Mahnaz Shekari | +8 more
ReferencesJack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62. Article PubMed Google Scholar Milà-Alomà M, Suárez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease. Ther Adv Neurol Disord. 2019;18(12):1756286419888819.
-
Nov 20, 2024 | 
mdpi.com | Hannah Duffy |Nicholas Ashton |Abbey Blair |Nathanael Hooper
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Nov 14, 2024 | 
bpspsychub.onlinelibrary.wiley.com | Joel Simrén |Nicholas Ashton |Marc Suárez-Calvet |Henrik Zetterberg
Recent developments in fluid and imaging biomarkers that reflect the key pathological hallmarks of Alzheimer's disease (AD)—deposits of extracellular amyloid-β (Aβ) and intracellular tau proteins—have transformed the perception of the disease in living individuals from a clinical syndrome to a biological continuum that begins prior to the onset of symptoms (Scheltens et al., 2021).
